Heart Failure D697300001
Prevent-HF Study
Study Title
A Phase III, Randomised, Double-blind, Placebo-controlled, Event-driven Study to Evaluate the Effect of Drug X in Combination with Dapagliflozin Compared with Dapagliflozin Alone on the Risk of Incident Heart Failure and Cardiovascular Death in Participants with Increased Risk of Developing Heart Failure
Study Duration
- Up to 2 years
Number of clinic visits
- Up to 11
Number of phone calls
- 0
Main Entry Criteria
- Over 40 years of age
- Established Cardiovascular disease
- Diagnosed with T2DM (Type 2 Diabetes Mellitus) and requiring treatment
There are additional eligibility requirements to enrol in this study. Our Study Doctor will review the study requirements and discuss your eligibility with you either over the telephone or at your first clinic visit.
Assessments
- ECG
- Blood pressure and pulse
- Blood and urine tests
You will receive all study-related procedures, medications, and laboratory services at no cost. In addition, you will be reimbursed per visit for your time and travel.
Study Status
- Currently enrolling participants at TrialsWest Osborne Park